BR112014000773A8 - Composições de nicotinamida e uso terapêutico das mesmas - Google Patents

Composições de nicotinamida e uso terapêutico das mesmas

Info

Publication number
BR112014000773A8
BR112014000773A8 BR112014000773A BR112014000773A BR112014000773A8 BR 112014000773 A8 BR112014000773 A8 BR 112014000773A8 BR 112014000773 A BR112014000773 A BR 112014000773A BR 112014000773 A BR112014000773 A BR 112014000773A BR 112014000773 A8 BR112014000773 A8 BR 112014000773A8
Authority
BR
Brazil
Prior art keywords
treatment
nicotinamide
compositions
therapeutic use
adhd
Prior art date
Application number
BR112014000773A
Other languages
English (en)
Other versions
BR112014000773A2 (pt
Inventor
Jan Cornelis Meijerink Hendrik
Changoer Lekhram
Blom Willem
Regina Visser Marinella
Willem Frijlink Henderik
Cornelus Eissens Anko
Original Assignee
Apet Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apet Holding B V filed Critical Apet Holding B V
Publication of BR112014000773A2 publication Critical patent/BR112014000773A2/pt
Publication of BR112014000773A8 publication Critical patent/BR112014000773A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES DE NICOTINAMIDA E O USO TERAPÊUTICO DAS MESMAS. A presente invenção se refere a composições e métodos para a profilaxia ou tratamento de deficiências na absorção e metabolismo de aminoácido essencial e/ou de uma patologia ou sintonia associado ao mesmo. Em particular, a invenção concerne o tratamento e/ou prevenção de TDAH, TDA e distúrbios do espectro autista. Os inventores atuais desenvolveram um método para a profilaxia ou tratamento de tais sintomas e/ou patologias associadas com uma deficiência na absorção e/ou metabolismo de aminoácido essencial, cujo método, declarado geralmente, depende da administração de nicotinamida, tipicamente em uma formulação de longa atuação a fim de superar as deficiências de formulações existentes, que se demonstraram inadequadas para o tratamento eficaz.
BR112014000773A 2011-07-14 2012-07-16 Composições de nicotinamida e uso terapêutico das mesmas BR112014000773A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507663P 2011-07-14 2011-07-14
EP11173963 2011-07-14
PCT/NL2012/050511 WO2013009186A1 (en) 2011-07-14 2012-07-16 Nicotinamide compositions and the therapeutic use thereof

Publications (2)

Publication Number Publication Date
BR112014000773A2 BR112014000773A2 (pt) 2017-06-13
BR112014000773A8 true BR112014000773A8 (pt) 2017-10-03

Family

ID=44800307

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014000773A BR112014000773A8 (pt) 2011-07-14 2012-07-16 Composições de nicotinamida e uso terapêutico das mesmas
BR112015000971A BR112015000971A2 (pt) 2011-07-14 2013-07-15 sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015000971A BR112015000971A2 (pt) 2011-07-14 2013-07-15 sistema de liberação de droga flutuante (fdds); e método para prover um sistema de liberação de droga flutuante (fdds)

Country Status (7)

Country Link
US (4) US20140234409A1 (pt)
EP (1) EP2731609A1 (pt)
BR (2) BR112014000773A8 (pt)
CA (1) CA2841731A1 (pt)
IL (1) IL236757B (pt)
MX (1) MX2014000517A (pt)
WO (1) WO2013009186A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014000517A (es) * 2011-07-14 2014-07-24 Apet Holding B V Composiciones de nicotinamida y el uso terapeutico de las mismas.
AU2013290875A1 (en) * 2012-07-16 2015-02-05 APET Holding B.V. Gastro-retentive drug delivery system
US20140271845A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Coated substrate compositions
US20190201360A1 (en) 2016-08-31 2019-07-04 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
EP3398600A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Modified release nicotinamide
WO2019027372A1 (en) * 2017-08-02 2019-02-07 Nanyang Technological University FLOATABLE PHARMACEUTICAL MICROCAPSULE COMPOSITION
WO2023166224A1 (en) * 2022-03-04 2023-09-07 APET Holding B.V. Gastroretentive formulations containing protein or peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (pt) * 1974-03-12 1980-04-02
US3976794A (en) 1974-06-03 1976-08-24 Scm Corporation Encapsulation of sugar and its use in sweetened coconut
JPH082781B2 (ja) 1988-10-18 1996-01-17 嘉明 川島 中空顆粒状医薬及びその製法
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
US4973467A (en) * 1989-10-13 1990-11-27 Natrol, Inc. Dietary supplement for adults
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
KR20090065524A (ko) * 2006-09-04 2009-06-22 파나세아 바이오테크 리미티드 프로그래머블 부력전달기술
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
WO2009051609A1 (en) 2007-10-19 2009-04-23 Pardee Joel D Metabolic enhancement therapy
JP2011506077A (ja) * 2007-12-11 2011-03-03 ナンヤン テクノロジカル ユニヴァーシティー 親水性活性化合物の送達のための中空多重層微小球
JP2012500230A (ja) * 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
MX2014000517A (es) 2011-07-14 2014-07-24 Apet Holding B V Composiciones de nicotinamida y el uso terapeutico de las mismas.

Also Published As

Publication number Publication date
US20180078503A1 (en) 2018-03-22
US10881614B2 (en) 2021-01-05
MX2014000517A (es) 2014-07-24
IL236757B (en) 2019-06-30
EP2731609A1 (en) 2014-05-21
BR112014000773A2 (pt) 2017-06-13
US20140234409A1 (en) 2014-08-21
BR112015000971A2 (pt) 2017-06-27
US20150202158A1 (en) 2015-07-23
WO2013009186A1 (en) 2013-01-17
CA2841731A1 (en) 2013-01-17
US20180140553A1 (en) 2018-05-24
IL236757A0 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
BR112014000773A8 (pt) Composições de nicotinamida e uso terapêutico das mesmas
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
UY34053A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
BR112013017845A2 (pt) agente antidiabético de abaixamento de lipídio
BR112015021931A2 (pt) Usos de composições farmacêuticas para prevenção e/ou tratamento de complicações do pulmão induzidas por radiação e da função pulmonar
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
BR112014027047A2 (pt) nova formulação
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]